Drug Discovery & Development
How one company is helping make complex medicines safer
Often, the most dangerous things in life are things that the human eye cannot see. This is true even for life-saving medicines. One company was founded to help the industry find these hidden particles and solve a key challenge in the development of complex drug products. Halo Labs’ CEO Rick Gordon spoke with ScienceBoard about how its low volume approach is providing a critical service for the drug development industry. Read More
Investment into regenerative medicine grows alongside company collaborations
Regenerative medicine is a relatively new area of medicine that involves significant research into how to harness the body's own healing mechanisms as treatments for a variety of diseases, including cardiovascular diseases, diabetes, and osteoarthritis. This is performed through the use of stem cell therapies, tissue engineering, and medical devices. The field is rapidly expanding, with many companies forming strategic research partnerships. Read More
Federal R&D funding for universities tops 3% in fiscal year 2021
Federally funded R&D for U.S. higher education universities grew 3.3% to $86.4 billion in fiscal year 2021 (end-September 30, 2021), according to the latest statistics from the National Science Foundation. Funding from the federal government accounted for 53% of the total and increased 3.7%. Read More
Newfound understanding of tissue migration can harness cancer spread
New research has uncovered mechanistic details in living tissue that explain how tissue exercises physical stresses to induce motion in vivo. The study, published in Nature Cell Biology on February 14, documents that the rear end of moving tissue plays a primary role in pushing tissue forward. This finding could be the basis for understanding organ development and the spread of cancer. Read More
Applied DNA and EvviVax publish data for potential cancer immunotherapy
Applied DNA Sciences and EvviVax have published a manuscript detailing a preclinical study showing that LinearDNA vaccines used for cancer immunotherapy produced a strong immune and specific antitumoral response in preclinical mouse models. The study investigated the use of the LinearDNA platform to produce DNA vaccines targeting either tumor-associated antigens (TAAs) or tumor-specific antigens (TSAs, or tumor neoantigens). Read More
Machine vision advances single-cell sequencing for small samples
The ability to sequence RNA in single cells has given scientists an unprecedented level of resolution in studying rare cell types. However, current approaches are designed to deal with a large number of cells, making it difficult to work with small samples. New research, published in Nature Methods on February 14, has described a technique using machine vision to detect cells and make single-cell RNA sequencing more efficient at a smaller scale. Read More
Colonic gene mapping provides insights into intestinal diseases
Researchers have used spatial transcriptomics to uncover an unprecedented view of the molecular regionalization of the murine colon. This research, published in Nature Communications on February 11, provides novel insights into inflammatory bowel disease. Read More
Bio-Rad develops antidaratumumab antibodies for drug monitoring
Bio-Rad Laboratories has launched a range of antidaratumumab antibodies that are specific for daratumumab (Darzalex) and inhibit the binding of the drug to its target, CD38. These highly specific and high-affinity recombinant antibodies are suitable for bioanalysis and drug monitoring of daratumumab and its biosimilars, according to the company. Read More
mRNA-based therapeutics pioneer innovation in the biopharmaceutical industry
In the age of COVID-19, many novel therapeutics have been brought to the forefront, most notably mRNA-based therapies. This technology has been used in two of the most prominent COVID-19 vaccines currently available in the U.S. under the U.S. Food and Drug Administration emergency use authorization. As a result, some companies are expanding mRNA-based technology to apply it to other therapies while further strengthening its use in vaccines. Read More
IsoPlexis uses proteomics to identify early factors of long COVID
IsoPlexis has published a study in Cell, led by the Institute for Systems Biology and the Seattle COVID Consortium, in which researchers used IsoPlexis' single-cell functional proteomics platform to identify factors that may predict sustained disease after COVID-19 infection, also known as post-acute sequelae of COVID-19 (PASC) or long COVID. Read More
Conferences
International Society for Cell and Gene Therapy Annual Meeting
May 4 - June 7
San Francisco, California United States
American Society for Mass Spectrometry Annual Conference
June 5-9
Minneapolis, Minnesota United States
American Society for Microbiology Microbe Meeting
June 9-13
District of Columbia United States
HPLC 2022
June 18-23
San Diego, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter